Background: Neoadjuvant chemotherapy (NAC) is increasingly being used to treat early breast
cancer. One of the main benefits to the surgeon is the potential to down-size the
tumour, thus facilitating breast-conserving surgery (BCS). Although the practice of
BCS following NAC is now widely established, there is relatively little data on the
impact of intrinsic breast cancer subtype on BCS conversion rates. The aim of this
study was to evaluate differences in BCS rates between intrinsic breast cancer subtypes
in patients undergoing NAC, in addition to clinical outcome.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Surgical OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2015 Published by Elsevier Inc.
